Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.

Ruxolitinib helped a man regrow hair after other treatments failed.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.

Topical Ruxolitinib may safely treat severe hair loss.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

JAK inhibitors are effective for long-term management of alopecia areata.

Topical tofacitinib may help regrow hair in children with alopecia totalis.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

JAK inhibitors show promise for treating alopecia areata but their effectiveness and safety are still debated.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

The name Janus is fitting for JAK inhibitors as they revolutionize dermatology treatments.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

JAK inhibitors can help some people with long-standing alopecia areata regrow hair, but many stop treatment due to limited effectiveness.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

Overexpression of PKCepsilon leads to increased TNFalpha, promoting metastatic squamous cell carcinoma in mice.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

KIT's role in skin cells is not entirely independent, as other cells can influence its function.

Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.